Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 52, Issue 1, Pages 81-89Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.110.077941
Keywords
genitourinary; molecular imaging; PET; PET/CT; acetate; choline; FDG; prostate
Funding
- National Institutes of Health-National Cancer Institute [R01-CA111613, R21-CA142426]
- NATIONAL CANCER INSTITUTE [R21CA142426, R01CA111613] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Prostate cancer is biologically and clinically a heterogeneous disease that makes imaging evaluation challenging. The role of imaging in prostate cancer should include diagnosis, localization, and characterization (indolent vs. lethal) of the primary tumor, determination of extracapsular spread, guidance and evaluation of local therapy in organ-confined disease, staging of locoregional lymph nodes, detection of locally recurrent and metastatic disease in biochemical relapse, planning of radiation treatment, prediction and assessment of tumor response to salvage and systemic therapy, monitoring of active surveillance and definition of a trigger for definitive therapy, and prognostication of time to hormone refractoriness in castrate disease and overall survival. To address these tasks effectively, imaging needs to be tailored to the specific phases of the disease in a patient-specific, risk-adjusted manner. In this article, I review the preclinical and clinical evidence on the potential and emerging role of PET with the 3 most commonly studied radiotracers in prostate cancer, namely F-18-FDG, F-18-or C-11-acetate, and F-18-or C-11-choline.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available